Additionally, real-world data reveals that approximately 77.1% of participants achieved at least a 5% reduction in body weight after 104 weeks of treatment, highlighting its effectiveness in practical settings
According to the Cochrane Collaborations tool for assessing risk of bias, all trials met the criteria for low risk of bias (Additional file 1: Table S1, Fig
145.40 Ships from UK, VAT incl
Several clinical trials utilizing imaging-based assessments have demonstrated significant reductions in visceral fat volume among patients treated with GLP-1 agonists
Additionally, semaglutide GLP-1 has been shown to slow down gastric emptying, leading to increased feelings of fullness and potentially altering nutrient absorption and digestion
The Centers for Disease Control and Prevention (CDC) reports that U.S